EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GNSS

GNSS

Genasys Inc.

Next earnings Aug 12, 2026 · consensus $0.02 EPS, $20.0M rev

Last earnings -5.4% on 2026-05-14

Avoid
$1.69
▲ +3.05%
$1.69▲ +9.74%
over 1Y
L $1.54EODHDH $2.58
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+5.6%
1M-19.9%
3M-3.4%
YTD-22.5%
1Y+9.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
C
Valuation
Fair value
Filings
Watch
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy

Revenue grew 69.8% YoY; but unprofitable (net margin -44.4%).

Revenue (FY2025) $40.8M · FY2025

Genasys Inc. shows $40.8M in FY2025 revenue (+69.8% YoY), a -44.4% net margin, and -835.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$47.0M$54.0M$46.7M$24.0M$40.8M
Gross profit$23.4M$27.3M$21.8M$10.2M$17.0M
Operating income$1.08M-$15.5M-$11.0M-$26.7M-$16.8M
Net income$704K-$16.2M-$18.4M-$31.7M-$18.1M
Diluted EPS$0.02-$0.44-$0.50-$0.72-$0.40
Net margin1.5%-30.0%-39.4%-132.2%-44.4%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$68.7M
EV / EBITDA—
EV / Sales1.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.7%
FCF yield-11.8%

Quality & risk

ROIC (est.)-538.3%
Free cash flow-$9.02M
Total debt$300K
Net cash$7.67M
Altman Z-Score-2.53 distress
Piotroski F-Score4/9

Capital returns

Buyback yield0.0%
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+0.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Material agreement2026-06-12
  2. 8-K Material agreement2026-05-14
  3. 10-Q Quarterly report2026-05-14
  4. 8-K Officer / director change2026-03-30
  5. 8-K Shareholder vote2026-03-18
  6. 8-K Earnings results2026-02-10
  7. 10-Q Quarterly report2026-02-10
  8. 8-K Officer / director change2026-01-30
  9. DEF 14A Proxy statement2026-01-28

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-092026-06-12open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-122026-05-14open ↗4Period ending 2026-03-262026-03-30open ↗3Period ending 2026-03-262026-03-30open ↗8-KPeriod ending 2026-03-262026-03-30open ↗4Period ending 2026-03-172026-03-19open ↗4Period ending 2026-03-172026-03-19open ↗4Period ending 2026-03-172026-03-19open ↗4Period ending 2026-03-172026-03-19open ↗8-KPeriod ending 2026-03-172026-03-18open ↗4Period ending 2026-02-182026-02-20open ↗

Quality score

C
ValueGrowthProfitHealthMom.
ValueA-
GrowthA+
ProfitabilityF
Financial healthD
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
Revenue
$40.8M
+69.8% YoY
Net margin
-44.4%
ROE
-835.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$40.8M+69.8%
Net income-$18.1M+42.9%
Gross profit$17.0M+66.4%
Operating income-$16.8M+37.1%
Diluted EPS-$0.40+44.4%
Cash & equivalents$7.97M+61.2%
Total assets$63.9M+18.4%
Total liabilities$61.7M+69.6%
Stockholders' equity$2.17M-87.7%
Gross: 41.6%Op.: -41.2%L/E: 28.47x

Frequently asked

Is Genasys Inc. (GNSS) a buy?
GNSS currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 69.8% YoY; but unprofitable (net margin -44.4%).
What is Genasys Inc.'s quality score?
GNSS scores 58.21568627450981/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000924383, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:41:40 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-26
Hagenbuch Lawrence F
Director
Award48.5K
2026-03-17
Dodd William H
Director
Award47.6K
2026-03-17
Fugate William Craig
Director
Award47.6K
2026-03-17
Malhotra R. Rimmy
Director
Award47.6K
2026-03-17
Schmeiser Susan Lee
Director
Award47.6K
2026-02-19
Dodd William H
Director
Buy25.4K @ $1.98$50.4K
2026-02-18
Dodd William H
Director
Buy27.00 @ $1.97$53.19
2026-01-26
Danforth Richard
CEO
Award400K
2025-12-24
HERNANDEZ-MONTEON CASSANDRA L
CFO/Treasurer/Secretary
Award70.0K

Dividends

Irregular
Yield (TTM)
—
Annual / share
—
Last ex-date
2016-06-13
Last amount
$0.01
ex 2016-06-13paid 2016-06-30$0.01
ex 2016-03-11paid 2016-03-30$0.01
ex 2016-01-13paid 2016-01-29$0.01

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-05-14Beat +184.0% est▼ -5.41%8-K ↗
2026-02-10Miss -96.1% est▲ 0.00%8-K ↗
2025-12-09Miss -17.6% est▲ +1.27%8-K ↗
2025-08-14Miss -30.7% est▲ +1.23%8-K ↗
2025-05-13—▼ -3.02%8-K ↗
2025-02-11—▼ -0.34%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Genasys expects annualized gross margins over 50% as it targets full-year gaap net income profitabilityBullish
seekingalpha.com· 2026-05-14
Genasys GNSS Q2 2026 Earnings Call TranscriptBullish
finance.yahoo.com· 2026-05-14
Genasys GNSS Q2 2026 Earnings Call TranscriptBullish
nasdaq.com· 2026-05-14
Genasys (GNSS) Q2 Earnings and Revenues Top EstimatesBullish
finance.yahoo.com· 2026-05-14
Genasys GAAP EPS of $0.02 beats by $0.05
seekingalpha.com· 2026-05-14
Arista (ANET) to Hit $11B in 2026 Revenues, $2B More Than 2025, Says CEOBullish
finance.yahoo.com· 2026-03-12

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score58 vs 67
Revenue growth69.8% vs 7.1%
Net margin-44.4% vs 10.5%
Return on equity-835.8% vs 12.3%
P/E— vs 25.5